Invicta Diagnostic Ltd vs Krishna Institute Of Medical Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Invicta Diagnostic Ltd is ₹ 64.5 as of 30 Oct 15:30 . The P/E Ratio of Invicta Diagnostic Ltd changed from 16.1 on March 2026 to 16.1 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Krishna Institute of Medical Sciences Ltd changed from 33.2 on March 2022 to 103.1 on March 2026 . This represents a CAGR of 25.44% over 5 years The Market Cap of Invicta Diagnostic Ltd changed from ₹ 79.2 crore on March 2026 to ₹ 79.2 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Krishna Institute of Medical Sciences Ltd changed from ₹ 11043 crore on March 2022 to ₹ 24910 crore on March 2026 . This represents a CAGR of 17.67% over 5 years The revenue of Invicta Diagnostic Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Krishna Institute of Medical Sciences Ltd for the Jun '26 is ₹ 1196 crore as compare to the Mar '26 revenue of ₹ 1086 crore. This represent the growth of 10.12% The ebitda of Invicta Diagnostic Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Krishna Institute of Medical Sciences Ltd for the Jun '26 is ₹ 240.8 crore as compare to the Mar '26 ebitda of ₹ 207.9 crore. This represent the growth of 15.82% The net profit of Invicta Diagnostic Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Krishna Institute of Medical Sciences Ltd changed from ₹ 95.2 crore to ₹ 37.4 crore over 9 quarters. This represents a CAGR of -33.98% The Dividend Payout of Invicta Diagnostic Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Krishna Institute of Medical Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Invicta Diagnostic Ltd

Invicta Diagnostic Limited was incorporated as Limited Liability Partnership under the name 'Invicta Diagnostic LLP' vide Certificate of Incorporation dated January 22, 2021 issued by Assistant Registrar of Companies, Central Registration Centre.
Further, Invicta Diagnostic LLP converted into a Private Limited Company as 'Invicta Diagnostic Private Limited' dated December 01, 2023.
Subsequently, Company converted from a Private Limited to a Public Limited Company, and the name was changed to 'Invicta Diagnostic Limited' and a fresh Certificate of Incorporation dated July 02, 2024 was issued by the Central Processing Centre. Invicta Diagnostic Limited is an innovative diagnostic chain in Mumbai Metropolitan Region (MMR) offering comprehensive radiology and pathology solutions.
It offer a one-stop solution for pathology and radiology testing services such as imaging (including radiology) and pathology/clinical laboratory to customers through a network, consisting of 8 diagnostic centres and 1 centralised laboratory across Mumbai Metropolitan Region in Maharashtra.

About Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Limited (KIMS) was erstwhile incorporated as Jagjit Singh and Sons Private Limited', a Private Limited Company on July 26, 1973 in Mumbai.
Subsequently, the name of the Company changed to Krishna Institute of Medical Sciences Private Limited' on January 2, 2004 and further upon its conversion to a Public Company, the name was changed to Krishna Institute of Medical Sciences Limited' on January 29, 2004. The Company is one of the largest corporate groups in India, with hospitals in Telangana, Andhra Pradesh & Maharashtra providing multi-disciplinary integrated services with a focus on tertiary and quaternary healthcare at affordable cost.
It is engaged in rendering medical and healthcare services.
It operate 12 multi-specialty hospitals under the 'KIMS Hospitals' brand, with an aggregate capacity of over 5000 beds.

FAQs for the comparison of Invicta Diagnostic Ltd and Krishna Institute of Medical Sciences Ltd

Which company has a larger market capitalization, Invicta Diagnostic Ltd or Krishna Institute of Medical Sciences Ltd?

Market cap of Invicta Diagnostic Ltd is 81 Cr while Market cap of Krishna Institute of Medical Sciences Ltd is 29,480 Cr

What are the key factors driving the stock performance of Invicta Diagnostic Ltd and Krishna Institute of Medical Sciences Ltd?

The stock performance of Invicta Diagnostic Ltd and Krishna Institute of Medical Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Invicta Diagnostic Ltd and Krishna Institute of Medical Sciences Ltd?

As of October 31, 2026, the Invicta Diagnostic Ltd stock price is INR ₹64.5. On the other hand, Krishna Institute of Medical Sciences Ltd stock price is INR ₹701.9.

How do dividend payouts of Invicta Diagnostic Ltd and Krishna Institute of Medical Sciences Ltd compare?

To compare the dividend payouts of Invicta Diagnostic Ltd and Krishna Institute of Medical Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.